Georgia Bio Signs-on Multi-Association Letter on Buy American Executive Order

Today Georgia Bio joins several other associations to sign-on the U.S. Chamber Letter to Secretary Mnuchin, Secretary Ross, Ambassador Lighthizer, and Director Kudlow.

The letter respectfully ask that the Trump administration defer moves to expand the reach of “Buy American” mandates to the medical equipment and biopharmaceutical sector during the present national emergency.


Please see below to read the full letter:

The undersigned organizations applaud the Trump administration’s focused response to the coronavirus pandemic. In particular, we appreciate the administration’s encouragement of public-private partnerships to quickly develop a vaccine for COVID-19 and expand the supply of medical countermeasures. We also commend the administration’s efforts to work with tech companies to map the spread of the coronavirus as well as FDA efforts to loosen regulations and increase testing capacities. American companies will do whatever it takes to support our country’s pandemic response and will continue to work hand in glove with government to get the job done.

While we are encouraged by this partnership and the administration’s ongoing labors with our international allies to respond to the pandemic with all available resources, we are concerned by reports of a draft “Buy American” executive order that could be counterproductive to these efforts. Such an order may delay the discovery of a COVID-19 vaccine and other treatments, worsen shortages of critically-needed medicines and medical products, and undermine prospects for economic recovery.

Now more than ever, U.S. industries require access to international supply chains to produce critically-needed medical products. The United States simply does not produce all of the raw materials or intermediate goods that are essential to drug development or production of the medical equipment needed to thwart this epidemic. Preventing federal agencies from sourcing medical equipment and pharmaceutical ingredients from abroad — or that are made with non-U.S. inputs — will only exacerbate the supply shortages racking the United States.

Further, as the world’s most innovative economy, the United States cannot shut itself off from the rest of the world. Turning our backs on trading partners during a crisis could damage our relationships long after this pandemic ends. If we implement localization requirements, many of our trade partners would assuredly follow our lead and limit imports from the United States.

For these reasons, we respectfully ask that the Trump administration defer moves to expand the reach of “Buy American” mandates to the medical equipment and biopharmaceutical sector during the present national emergency. This pandemic has raised awareness of vulnerabilities in supply chains, and American industries look forward to working with the administration to solve those challenges with well-thought-out solutions, but those efforts should be deferred until the national emergency is passed.

Today, our shared priority must be to defeat COVID-19. The U.S. business community is committed to doing whatever it takes — working in close partnership with you — to achieve this goal.

By Maria Thacker Goethe October 22, 2025
“Evolving FTC and DOJ policies leave investors and innovators navigating a cautious M&A landscape
October 6, 2025
Atlanta, GA — October 6 — Georgia Life Sciences today announced the launch of Vitals, a new podcast series developed in partnership with Cloudcast Media, a leader in branded podcast production. The series will spotlight the people, ideas, and innovations shaping the future of Georgia’s rapidly growing life sciences sector. Hosted by Georgia Life Sciences’ CEO, Maria Thacker Goethe, Vitals will feature in-depth conversations with scientists, entrepreneurs, investors, educators, policymakers, and patient advocates. Each episode will explore the challenges and opportunities facing Georgia’s life sciences ecosystem—spanning biopharma, medical technology, digital health, and advanced manufacturing. “Vitals gives us a powerful platform to showcase the remarkable work happening within our state,” said Maria Thacker Goethe. “By sharing these stories, we’re highlighting not only groundbreaking science but also the collaboration and talent that make Georgia such a vibrant hub for health innovation.” Cloudcast Media, known for its expertise in storytelling and high-quality podcast production, will bring industry insights and technical support to ensure the series reaches audiences across Georgia and beyond. “We’re proud to partner with Georgia Life Sciences on Vitals,” said Charles Parisi, Founder and CEO of Cloudcast. “This series will elevate the voices of innovators who are advancing science, improving patient outcomes, and building Georgia’s reputation as a global life sciences leader. We are very excited that Cloudcast Atlanta can play a role in supporting Maria and the impactful work of Georgia Life Sciences.” The first episode of Vitals launched today and is available on Apple Podcasts, Spotify, and other major streaming platforms, as well as through the Georgia Life Sciences website.
October 1, 2025
September 30, 2025 WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on Most Favored Nation policies: "For too many years, Americans have subsidized the research and development necessary to bring newer and better medicines to patients around the world. As we saw with defense spending and NATO, the solution is not to weaken a strategically important American industry, but for other countries to pay their fair share. “Today’s announcement in the Oval Office highlights the problems with a drug delivery system where half of the cost of innovative medicines goes to middlemen and distributors, and where the supply chain distorts prices paid by the American people. We support a new framework that addresses the cost of medicines by simplifying the system - and making medicines directly available to patients. “But importing socialist price controls through most-favored nation policies fundamentally does not address the imbalance in international pricing for innovative medicines. MFN will not lower the out-of-pocket prices that most Americans pay for medicines. Even worse, it will jeopardize the entrepreneurial spirit and deter the capital necessary for a vibrant and essential American biotechnology industry to thrive and may cause most harm to small and midsize biotech companies, which are responsible for discovering more than half of all new treatments. “Without these biotech innovators and a free-market system, we risk slower scientific progress, decreased access to new medicines, compromised national security, fewer American jobs and perhaps most tragically, a diminished hope for those suffering with illness and disease. There are much better ways to address this problem than MFN.” ###
MORE POSTS